Validated diabetes model tweaks trial design, therapy

Researchers have validated in the lab a computer model that predicts key information about nasal insulin treatment regimens for Type 1 diabetes. The work, which confirms that modeling can optimize the efficacy of nasal insulin immunotherapy, also supports the use of humanized platforms in the design of clinical trials.

The Type 1 Diabetes PhysioLab Platform models disease pathogenesis based on non-obese diabetic mice. The findings, by a La Jolla Institute team led by Matthias von Herrath, show the platform can predict critical Type 1 diabetes biomarkers. It streamlines experimental design by pinpointing when biomarkers associated with protection in mice are induced.

The platform was developed over two years with input from independent experts. It simulates autoimmune processes and the subsequent destruction of insulin-producing pancreatic beta cells, the underlying cause of Type 1 diabetes, from birth through onset of the disease.

"Virtual Optimization of Nasal Insulin Therapy Predicts Immunization Frequency to be Crucial for Diabetes Protection" appears in the December issue of Diabetes.

- see the article
- here's the paper summary and article access

Suggested Articles

There's no evidence personal patient information leaked during the 11-week breach, but the same can't be said about Sangamo's own secrets.

Through a new online tracker, AllTrials names sponsors who fail to report clinical trial results on time per the FDAAA Final Rule.

The new solution aims to streamline the incorporation of human genomic data into clinical trial designs.